APA (7th ed.) Citation

V, D. C., E, C., J, T., BN, L., MJA, K., K, P., . . . ME, H. (2026). Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease. Alzheimer's research & therapy, 18(1), . https://doi.org/10.1186/s13195-026-02025-4

Chicago Style (17th ed.) Citation

V, Di Caro, et al. "Impact of Zervimesine on the Neuroinflammatory Biomarker GFAP and Related Proteomic Molecular Correlates in Plasma of Participants from a Phase 2 Clinical Trial in Alzheimer's Disease." Alzheimer's Research & Therapy 18, no. 1 (2026). https://doi.org/10.1186/s13195-026-02025-4.

MLA (9th ed.) Citation

V, Di Caro, et al. "Impact of Zervimesine on the Neuroinflammatory Biomarker GFAP and Related Proteomic Molecular Correlates in Plasma of Participants from a Phase 2 Clinical Trial in Alzheimer's Disease." Alzheimer's Research & Therapy, vol. 18, no. 1, 2026, https://doi.org/10.1186/s13195-026-02025-4.